![Lars Kober](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Origen de la red de primer grado Lars Kober.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
Neurokey A/S
![]() Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.
10
| Extinct | Pharmaceuticals: Major | 10 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Lars Kober a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
H. LUNDBECK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
Roche Pharmaceuticals, Inc.
![]() Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Thesan Pharmaceuticals, Inc.
![]() Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thesan Pharmaceuticals, Inc. provides novel therapeutics for disorders of the skin. The company focuses on the discovery and development of new chemical entities that provide improved treatment options to patients. Thesan Pharmaceuticals was founded in 2011 by Edward P. Monaghan and is headquartered in Carlsbad, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
NTG NORDIC TRANSPORT GROUP A/S | Trucking | Public Communications Contact Corporate Officer/Principal | |
Novo Holdings AS (Denmark)
![]() Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal | |
Novartis Pharmaceuticals UK Ltd.
![]() Novartis Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals UK Ltd. manufactures medicines and drugs. The company is headquartered in Camberley, the United kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
ALK-ABELLÓ A/S | Biotechnology | Corporate Officer/Principal | |
Teknologisk Institut
![]() Teknologisk Institut Miscellaneous Commercial ServicesCommercial Services Teknologisk Institut develops, applies, and disseminates research- and technology-based knowledge for the Danish business. It is an independent, non-profit institution that provides training courses and conferences including information technology courses; energy and construction; project; personal development; leadership; productivity, measuring technology, and logistics; quality; food and environment; communication; sales and marketing; and human resource, law, and economics. In addition, it also carries out consultancy and standardization activities. The firm provides services in business areas such as building and construction; business and industrial development; chemistry and biotechnology; energy and climate; environment, working environment, and health; food and packaging; industrial measurements and control; industrial production and development; meat industry solutions; productivity and management; surfaces and microtechnology; and transport and logistics. The company was founded by Gunnar Gregersen in 1906 and is headquartered in Taastrup, Denmark. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Danske Private Equity A/S
![]() Danske Private Equity A/S Investment ManagersFinance Danske Private Equity A/S (DPE) is a private equity fund of funds investment firm founded in 1999. The firm is headquartered in Lyngby. | Investment Managers | Corporate Officer/Principal | |
Hoffman-LaRoche F & Co. AG
![]() Hoffman-LaRoche F & Co. AG Miscellaneous Commercial ServicesCommercial Services Hoffman-LaRoche F & Co. AG is a Swiss company. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
University of Copenhagen | College/University | Graduate Degree Doctorate Degree Masters Business Admin Doctorate Degree Doctorate Degree | |
Danmarks Farmaceutiske Universitet | College/University | Graduate Degree Doctorate Degree | |
Azanta Danmark A/S
![]() Azanta Danmark A/S Pharmaceuticals: MajorHealth Technology Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
SEED Capital Management I/S
![]() SEED Capital Management I/S Investment ManagersFinance SEED Capital Management I/S is an Independent Venture Capital firm founded in 2004. The company is headquartered in Copenhagen, Denmark. | Investment Managers | Private Equity Investor Private Equity Investor | |
Celltrix AB
![]() Celltrix AB Medical SpecialtiesHealth Technology Celltrix AB manufactures medical devices. It develops novel and injectable dermal filler for reconstructive cosmetic surgery, based on microbeads of cross-linked gelatine. The company was founded in December 2003 by Kjell Gösta Conny Nilsson and is headquartered in Malmö, Sweden. | Medical Specialties | Director/Board Member | |
Glycom A/S
![]() Glycom A/S BiotechnologyHealth Technology Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark. | Biotechnology | Director of Finance/CFO | |
The European Commission | General Government | Corporate Officer/Principal | |
Novo Ventures 1 A/S
![]() Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Private Equity Investor | |
Bok Holding A/S
![]() Bok Holding A/S BiotechnologyHealth Technology Bok Holding A/S is a holding company that operates as a biotechnology company that researches and develops cancer treatment solutions. It develops the ZAS platform technology which efficiently enhances the effect of current anti-cancer drugs and reduces toxicity. The firm employs molecular techniques commonly known as molecular breeding or directed enzyme evolution which can activate anti-cancer drugs. The company was founded by Zoran Gojkovic on November 22, 2001 and is headquartered in Gentofte, Denmark. | Biotechnology | Chairman Director/Board Member | |
EpiTherapeutics ApS
![]() EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member | |
Statens Serum Institute | College/University | Doctorate Degree | |
CanImGuide Therapeutics AB
![]() CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
BKG Pharma ApS
![]() BKG Pharma ApS Pharmaceuticals: MajorHealth Technology BKG Pharma ApS develops and commercializes novel antibiotics against multidrug-resistant bacteria. It conducts research and development on treatment for multi-resistant infections such as resistance to chemotherapy. The company was founded by Birgit K. Giwercman in 2004 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Reapplix A/S
![]() Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | Medical Distributors | Director/Board Member | |
ACARIX AB | Medical Specialties | Director/Board Member | |
Contera Pharma ApS
![]() Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Director/Board Member | |
Minervax ApS
![]() Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Medical Specialties | Director/Board Member | |
Acesion Pharma ApS
![]() Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
OncoNOx ApS
![]() OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Galecto Biotech ApS
![]() Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Evolva A/S | Director/Board Member | ||
HERANTIS PHARMA OYJ | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
CURASIGHT A/S | Medical Specialties | Director/Board Member | |
BOLT BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Outpost Medicine, Inc.
![]() Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
GUBRA A/S | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
C- ApS | Founder | ||
Allarity Therapeutics A/S
![]() Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Pharmaceuticals: Major | Chairman | |
Besst-Test ApS | Chairman | ||
Biotech Af 14 Maj 2014 ApS | Director/Board Member | ||
Victorious Medical Systems ApS | Director/Board Member |
Estadísticas
Internacional
Dinamarca | 39 |
Estados Unidos | 5 |
Suecia | 4 |
Japón | 2 |
Reino Unido | 2 |
Sectorial
Health Technology | 30 |
Commercial Services | 5 |
Finance | 5 |
Consumer Services | 4 |
Transportation | 2 |
Operativa
Director/Board Member | 70 |
Corporate Officer/Principal | 23 |
Chairman | 12 |
Independent Dir/Board Member | 11 |
Private Equity Investor | 7 |
Las relaciones más conectadas
- Bolsa de valores
- Insiders
- Lars Kober
- Conexiones Empresas